Loading
A phase 2/3 trial of Pembrolizumab in merkel cell carcinoma, run by TuHURA Biosciences, Inc., now recruiting.
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma is a phase 2/3 interventional study registered as NCT06947928 by TuHURA Biosciences, Inc., with 118 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: IFx-Hu2.0, Placebo, Pembrolizumab. Conditions listed: Advanced Or Metastatic Merkel Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merkel cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Merkel cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Merkel cell carcinoma, Pembrolizumab.
Shares Merkel cell carcinoma, Pembrolizumab.
Shares Merkel cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Merkel cell carcinoma, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/